newsfilter
← Latest News
Business Wire·

Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update

Total Revenue of $13.0 Million in 2Q 2021; TAZVERIK® Net Product Revenues of $8.0 Million Revised Commercial Strategy and Operating Plan to Accelerate Adoption of TAZVERIK® and Focus Investment on Important Value-Driving Programs IND Clearance